Organovo reports $11.3M cash balance in FY24
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Should l Buy ?
Source: SeekingAlpha
Financial Overview: Organovo reported a preliminary cash balance of approximately $11.3 million as of March 31, 2025, with a net cash utilization of about $2.0M - $2.2M during the fourth quarter.
Future Expectations: The company anticipates receiving a $5 million milestone payment related to a Phase 2 clinical trial for its FXR agonist within the next year, and expects to meet Nasdaq listing requirements.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
